Clinical Trial Update: Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence [Phase 2]

View source ↗

Summary

Phase 2 trial investigating donafenib plus tislelizumab as adjuvant therapy for hepatocellular carcinoma at high risk of recurrence.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Donafenib (donafenib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN